KEGG   DRUG: Alectinib hydrochloride
Entry
D10450                      Drug                                   
Name
Alectinib hydrochloride (JAN);
Alecensa (TN)
Product
ALECENSA (Genentech)
Formula
C30H34N4O2. HCl
Exact mass
518.2449
Mol weight
519.0775
Structure
Simcomp
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG03136  ALK inhibitor
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Therapeutic category: 4291
ATC code: L01ED03
Chemical structure group: DG01625
Product (DG01625): D10450<JP/US>
Efficacy
Antineoplastic, Anaplastic lymphoma kinase (ALK) inhibitor
  Disease
Non-small cell lung cancer (ALK positive) [DS:H00014]
Target
EML4-ALK [HSA_VAR:238v2] [HSA:238] [KO:K05119]
  Network
N10004  Second/third-generation tyrosine kinase inhibitor to ALK fusion
  Pathway
hsa05200  Pathways in cancer
hsa05223  Non-small cell lung cancer
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01ED Anaplastic lymphoma kinase (ALK) inhibitors
     L01ED03 Alectinib
      D10450  Alectinib hydrochloride (JAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Alectinib
    D10450  Alectinib hydrochloride (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10450  Alectinib hydrochloride (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG03136  ALK inhibitor
    DG01625  Alectinib
     D10450  Alectinib hydrochloride
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG01625  Alectinib
     D10450  Alectinib hydrochloride
Drug classes [BR:br08332]
 Antineoplastic
  DG03136  ALK inhibitor
   D10450  Alectinib hydrochloride
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   ALK family
    EML4-ALK [HSA_VAR:238v2]
     D10450  Alectinib hydrochloride (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10450
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10450
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10450
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10450
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10450
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10450
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG03136  ALK inhibitor
    DG01625  Alectinib
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG01625  Alectinib
Other DBs
PubChem: 172232543
ChEBI: 62268
LinkDB
KCF data

ATOM        37
            1   C1x C     6.8600  -19.0400
            2   O2x O     6.8600  -20.4400
            3   C1x C     8.0724  -21.1400
            4   C1x C     9.2849  -20.4400
            5   N1y N     9.2849  -19.0400
            6   C1x C     8.0724  -18.3400
            7   C1y C    10.5160  -18.3290
            8   C1x C    11.7212  -19.0247
            9   C1x C    12.9335  -18.3246
            10  N1y N    12.9335  -16.9246
            11  C1x C    11.7283  -16.2289
            12  C1x C    10.5159  -16.9290
            13  C8y C    14.1514  -16.2212
            14  C8x C    15.3634  -16.9207
            15  C8y C    16.5757  -16.2206
            16  C8y C    16.5755  -14.8206
            17  C8x C    15.3636  -14.1210
            18  C8y C    14.1512  -14.8212
            19  C1b C    12.9386  -14.1213
            20  C1a C    11.7268  -14.8211
            21  C1z C    17.7882  -16.9204
            22  C8y C    19.0006  -16.2203
            23  C8y C    19.0004  -14.8203
            24  C5x C    17.7879  -14.1204
            25  N4x N    20.3321  -16.6527
            26  C8y C    21.1549  -15.5200
            27  C8y C    20.3318  -14.3875
            28  C8x C    22.5472  -15.3735
            29  C8y C    23.1165  -14.0944
            30  C8x C    22.2934  -12.9619
            31  C8x C    20.9011  -13.1084
            32  C3b C    24.4948  -13.9491
            33  N3a N    25.8471  -13.7968
            34  O5x O    17.7876  -12.7400
            35  C1a C    18.4662  -18.1603
            36  C1a C    17.0480  -18.1334
            37  X   Cl   24.6400  -19.6700
BOND        41
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     5   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 1
            12   11  12 1
            13    7  12 1
            14   10  13 1
            15   13  14 2
            16   14  15 1
            17   15  16 2
            18   16  17 1
            19   17  18 2
            20   13  18 1
            21   18  19 1
            22   19  20 1
            23   15  21 1
            24   21  22 1
            25   22  23 2
            26   23  24 1
            27   16  24 1
            28   22  25 1
            29   25  26 1
            30   26  27 1
            31   23  27 1
            32   26  28 2
            33   28  29 1
            34   29  30 2
            35   30  31 1
            36   27  31 2
            37   29  32 1
            38   32  33 3
            39   24  34 2
            40   21  35 1
            41   21  36 1

» Japanese version   » Back

KEGG   DRUG: Ceritinib
Entry
D10551                      Drug                                   
Name
Ceritinib (JAN/USAN/INN);
Zykadia (TN)
Product
ZYKADIA (Novartis Pharmaceuticals Corporation)
Formula
C28H36ClN5O3S
Exact mass
557.2227
Mol weight
558.1351
Structure
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG03136  ALK inhibitor
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
Remark
Therapeutic category: 4291
ATC code: L01ED02
Product: D10551<JP/US>
Efficacy
Antineoplastic, Anaplastic lymphoma kinase (ALK) inhibitor
  Disease
Non-small cell lung cancer (ALK positive) [DS:H00014]
Target
EML4-ALK [HSA_VAR:238v2] [HSA:238] [KO:K05119]
  Network
N10004  Second/third-generation tyrosine kinase inhibitor to ALK fusion
  Pathway
hsa05200  Pathways in cancer
hsa05223  Non-small cell lung cancer
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01ED Anaplastic lymphoma kinase (ALK) inhibitors
     L01ED02 Ceritinib
      D10551  Ceritinib (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Ceritinib
    D10551  Ceritinib (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10551  Ceritinib (JAN/USAN/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG03136  ALK inhibitor
    D10551  Ceritinib
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   D10551  Ceritinib
Drug classes [BR:br08332]
 Antineoplastic
  DG03136  ALK inhibitor
   D10551  Ceritinib
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   ALK family
    EML4-ALK [HSA_VAR:238v2]
     D10551  Ceritinib (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10551
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10551
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10551
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10551
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10551
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10551
Other DBs
CAS: 1032900-25-6
PubChem: 254741513
PDB-CCD: 4MK[PDBj]
LinkDB
KCF data

ATOM        38
            1   C1x C     5.6700  -17.9200
            2   N1x N     5.6700  -19.3200
            3   C1x C     6.8824  -20.0200
            4   C1x C     8.0949  -19.3200
            5   C1y C     8.0949  -17.9200
            6   C1x C     6.8824  -17.2200
            7   C8y C     9.3260  -17.2090
            8   C8y C    10.5312  -17.9047
            9   C8x C    11.7435  -17.2046
            10  C8y C    11.7435  -15.8046
            11  C8y C    10.5383  -15.1089
            12  C8x C     9.3259  -15.8090
            13  O2a O    10.5385  -13.7204
            14  C1a C    10.5316  -19.3196
            15  N1b N    12.9614  -15.1012
            16  C8y C    14.1734  -15.8007
            17  N5x N    14.1740  -17.2196
            18  C8x C    15.3867  -17.9190
            19  C8y C    16.5989  -17.2185
            20  C8y C    16.5982  -15.7996
            21  N5x N    15.3855  -15.1002
            22  X   Cl   17.8056  -17.9145
            23  N1b N    17.7954  -15.1079
            24  C8y C    19.0016  -15.8039
            25  C8x C    19.0023  -17.2196
            26  C8x C    20.2151  -17.9190
            27  C8x C    21.4272  -17.2184
            28  C8x C    21.4265  -15.8027
            29  C8y C    20.2137  -15.1033
            30  S4a S    20.2131  -13.7201
            31  O3c O    21.6131  -13.7201
            32  O3c O    18.8131  -13.7201
            33  C1c C    20.2131  -12.3201
            34  C1a C    21.4382  -11.6127
            35  C1a C    19.0134  -11.6274
            36  C1c C     9.3498  -13.0337
            37  C1a C     8.1658  -13.7170
            38  C1a C     9.3498  -11.6203
BOND        41
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     5   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12   11  12 2
            13    7  12 1
            14   11  13 1
            15    8  14 1
            16   10  15 1
            17   15  16 1
            18   16  17 2
            19   17  18 1
            20   18  19 2
            21   19  20 1
            22   20  21 2
            23   16  21 1
            24   19  22 1
            25   20  23 1
            26   23  24 1
            27   24  25 2
            28   25  26 1
            29   26  27 2
            30   27  28 1
            31   28  29 2
            32   24  29 1
            33   29  30 1
            34   30  31 2
            35   30  32 2
            36   30  33 1
            37   33  34 1
            38   33  35 1
            39   13  36 1
            40   36  37 1
            41   36  38 1

» Japanese version   » Back

KEGG   DRUG: Brigatinib
Entry
D10866                      Drug                                   
Name
Brigatinib (JAN/USAN);
Alunbrig (TN)
Product
ALUNBRIG (Takeda Pharmaceuticals America)
Formula
C29H39ClN7O2P
Exact mass
583.2591
Mol weight
584.0924
Structure
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG03136  ALK inhibitor
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Therapeutic category: 4291
ATC code: L01ED04
Product: D10866<JP/US>
Efficacy
Antineoplastic, Anaplastic lymphoma kinase (ALK) inhibitor
  Disease
Non-small cell lung cancer (ALK positive) [DS:H00014]
Target
EML4-ALK [HSA_VAR:238v2] [HSA:238] [KO:K05119]
  Network
N10004  Second/third-generation tyrosine kinase inhibitor to ALK fusion
  Pathway
hsa05200  Pathways in cancer
hsa05223  Non-small cell lung cancer
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01ED Anaplastic lymphoma kinase (ALK) inhibitors
     L01ED04 Brigatinib
      D10866  Brigatinib (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Brigatinib
    D10866  Brigatinib (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10866  Brigatinib (JAN/USAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG03136  ALK inhibitor
    D10866  Brigatinib
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10866  Brigatinib
Drug classes [BR:br08332]
 Antineoplastic
  DG03136  ALK inhibitor
   D10866  Brigatinib
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   ALK family
    EML4-ALK [HSA_VAR:238v2]
     D10866  Brigatinib (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10866
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10866
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10866
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10866
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10866
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10866
Other DBs
CAS: 1197953-54-0
PubChem: 319902666
PDB-CCD: 6GY[PDBj]
LinkDB
KCF data

ATOM        40
            1   C8y C    22.4000  -17.0100
            2   C8x C    22.4000  -18.4100
            3   C8x C    23.6124  -19.1100
            4   C8x C    24.8249  -18.4100
            5   C8x C    24.8249  -17.0100
            6   C8y C    23.6124  -16.3100
            7   N1b N    21.1876  -16.3100
            8   C8y C    19.9921  -17.0004
            9   N5x N    18.8047  -16.3149
            10  C8y C    17.5923  -17.0150
            11  N5x N    17.5924  -18.4150
            12  C8x C    18.7797  -19.1004
            13  C8y C    19.9921  -18.4004
            14  N1b N    16.3610  -16.3040
            15  C8y C    15.1603  -16.9973
            16  C8x C    13.9756  -16.3133
            17  C8x C    12.7632  -17.0133
            18  C8y C    12.7632  -18.4133
            19  C8x C    13.9479  -19.0973
            20  C8y C    15.1603  -18.3973
            21  N1y N    11.5350  -19.1226
            22  C1x C    10.3284  -18.4261
            23  C1x C     9.1160  -19.1262
            24  C1y C     9.1161  -20.5262
            25  C1x C    10.3226  -21.2227
            26  C1x C    11.5350  -20.5226
            27  N1y N     7.8988  -21.2292
            28  C1x C     6.6865  -20.5295
            29  C1x C     5.4742  -21.2296
            30  N1y N     5.4744  -22.6296
            31  C1x C     6.6867  -23.3293
            32  C1x C     7.8990  -22.6292
            33  C1a C     4.2599  -23.3310
            34  X   Cl   21.2296  -19.1149
            35  P1a P    23.6124  -14.9102
            36  O3b O    23.6124  -13.5102
            37  C1a C    25.0124  -14.9102
            38  C1a C    22.2124  -14.9102
            39  O2a O    16.4004  -19.1134
            40  C1a C    16.4004  -20.5134
BOND        44
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     1   7 1
            8     7   8 1
            9     8   9 2
            10    9  10 1
            11   10  11 2
            12   11  12 1
            13   12  13 2
            14    8  13 1
            15   10  14 1
            16   14  15 1
            17   15  16 2
            18   16  17 1
            19   17  18 2
            20   18  19 1
            21   19  20 2
            22   15  20 1
            23   18  21 1
            24   21  22 1
            25   22  23 1
            26   23  24 1
            27   24  25 1
            28   25  26 1
            29   21  26 1
            30   24  27 1
            31   27  28 1
            32   28  29 1
            33   29  30 1
            34   30  31 1
            35   31  32 1
            36   27  32 1
            37   30  33 1
            38   13  34 1
            39    6  35 1
            40   35  36 2
            41   35  37 1
            42   35  38 1
            43   20  39 1
            44   39  40 1

» Japanese version   » Back

KEGG   DRUG: Lorlatinib
Entry
D11012                      Drug                                   
Name
Lorlatinib (JAN/USAN/INN);
Lorbrena (TN)
Product
LORBRENA (Pfizer Laboratories Div Pfizer)
Formula
C21H19FN6O2
Exact mass
406.1554
Mol weight
406.413
Structure
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG03136  ALK inhibitor
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
Metabolizing enzyme inducer
 DG02853  CYP3A/CYP3A4 inducer
Transporter inducer
 DG01893  ABCB1 inducer
Remark
Therapeutic category: 4291
ATC code: L01ED05
Product: D11012<JP/US>
Efficacy
Antineoplastic, Tyrosine kinase inhibitor
  Disease
Non-small cell lung cancer (ALK positive) [DS:H00014]
Target
EML4-ALK [HSA_VAR:238v2] [HSA:238] [KO:K05119]
ALK (CD246) [HSA:238] [KO:K05119]
ROS1 [HSA:6098] [KO:K05088]
  Network
N10004  Second/third-generation tyrosine kinase inhibitor to ALK fusion
  Pathway
hsa05200  Pathways in cancer
hsa05223  Non-small cell lung cancer
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551]
Interaction
CYP induction: CYP3A [HSA:1576 1577 1551]
Transporter induction: ABCB1 [HSA:5243]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01ED Anaplastic lymphoma kinase (ALK) inhibitors
     L01ED05 Lorlatinib
      D11012  Lorlatinib (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Lorlatinib
    D11012  Lorlatinib (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D11012  Lorlatinib (JAN/USAN/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG03136  ALK inhibitor
    D11012  Lorlatinib
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   D11012  Lorlatinib
 Metabolizing enzyme inducer
  DG02853  CYP3A/CYP3A4 inducer
   D11012  Lorlatinib
 Transporter inducer
  DG01893  ABCB1 inducer
   D11012  Lorlatinib
Drug classes [BR:br08332]
 Antineoplastic
  DG03136  ALK inhibitor
   D11012  Lorlatinib
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    ROS1
     D11012  Lorlatinib (JAN/USAN/INN) <JP/US>
   ALK family
    ALK (CD246)
     D11012  Lorlatinib (JAN/USAN/INN) <JP/US>
    EML4-ALK [HSA_VAR:238v2]
     D11012  Lorlatinib (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11012
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11012
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11012
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11012
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D11012
 Drug transporters
  D11012
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11012
Other DBs
CAS: 1454846-35-5
PubChem: 346930790
ChEBI: 143117
PDB-CCD: 5P8[PDBj]
LinkDB
KCF data

ATOM        30
            1   C8y C    18.0153  -18.0595
            2   C8y C    18.0153  -19.3981
            3   N5x N    19.1531  -20.0674
            4   C8x C    20.3579  -19.3981
            5   C8y C    20.3579  -18.0595
            6   C8x C    19.1531  -17.3902
            7   C8y C    21.4957  -17.3902
            8   O2x O    16.8775  -17.3902
            9   C1y C    16.8775  -16.0516
            10  C8y C    15.7397  -15.3823
            11  C8y C    22.7673  -17.7918
            12  N4y N    23.7105  -16.7209
            13  N5x N    22.7673  -15.5100
            14  C8y C    21.4957  -16.0516
            15  C1x C    19.6216  -15.3823
            16  C8y C    15.7397  -14.0437
            17  C8x C    14.6018  -13.3744
            18  C8x C    13.4640  -14.0437
            19  C8y C    13.4640  -15.3823
            20  C8x C    14.6018  -16.0516
            21  X   F    12.3262  -16.0516
            22  C5x C    17.7476  -13.3744
            23  N1y N    19.6216  -14.0437
            24  O5x O    17.7476  -12.0358
            25  C1a C    18.0395  -15.3870
            26  N1a N    16.8533  -20.0628
            27  C1a C    25.0491  -16.7209
            28  C3b C    23.1766  -19.0664
            29  N3a N    23.5231  -20.3594
            30  C1a C    20.7393  -13.2563
BOND        33
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     1   8 1
            9     8   9 1
            10    9  10 1
            11    7  11 2
            12   11  12 1
            13   12  13 1
            14   13  14 2
            15    7  14 1
            16   15  14 1
            17   10  16 2
            18   16  17 1
            19   17  18 2
            20   18  19 1
            21   19  20 2
            22   10  20 1
            23   19  21 1
            24   22  23 1
            25   22  16 1
            26   22  24 2
            27   23  15 1
            28    9  25 1 #Up
            29    2  26 1
            30   12  27 1
            31   11  28 1
            32   28  29 3
            33   23  30 1

» Japanese version   » Back

DBGET integrated database retrieval system